Signum Biosciences, Inc.

Princeton University

Jeffry B Stock

Maxwell Stock

Michael Voronkov

Seung-Yub Lee

Joel Gordon

Eduardo Perez

Keshava Rapole

Shuyi Chen

Haoming Gu

Jinglong Chen

Zhu Li

Scott Bradley Vafai

Gregory Stock

Jose Fernandez

Peter Michael Wolanin

Kristen Huber

Karl Rouzard

Gopal Sarngadharan

Scott Vafai

Method of preparing a botanical extract that includes contacting a raw botanical with a solvent having a dielectric constant ranging from about 2.3 to about 25 and allowing the mixture to reside for a sufficient time to obtain a crude extract; filtering out remaining raw botanical and evaporating the solvent from the crude extract under reduced pressure to obtain a dried crude extract; washing the dried crude extract with a polar solvent having a dielectric constant of no less than 30, heating the resulting mixture, and allowing to cool to ambient; collecting a filtrate from the above cooled mixture; washing the collected filtrate with a non-polar solvent having a dielectric constant of no more than 2.0; and filtering and drying the mixture to obtain the botanical extract.

Methods for preparing botanical extracts

The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.

Compounds, compositions and methods for making the same

Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.

Isoprenyl compounds and methods thereof

EHT extract including a mixture of late eluting tryptamides and early eluting tryptamides in a weight ratio of at least about 7:1 late eluting tryptamides:early eluting tryptamides, wherein the EHT extract includes at least 30% eicosanoyl-5-hydroxytryptamide, based on the total weight of the tryptamides in the EHT extract.

Tryptamide compositions and methods of use

Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects.

Use of anti-bacterial agents for the treatment of epithelial-related conditions

Isoprenyl compounds

Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease).

Cysteinyl compounds, compositions and methods of use

The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions.

Topical compositions and methods for epithelial-related conditions

The invention encompasses novel compositions containing a methylation modifying compound isolated from botanical raw materials, including a fruit of the genus, and microbial raw materials, methods of making such compositions, and methods of treating or preventing human disease using such compositions. The methylation modifying compound in botanical extracts of the present invention can dramatically increase the level of methylation of PP2A, thus increasing cognitive function, particularly in persons suffering from or prone to developing Alzheimer's disease.

Compositions and methods for enhancing cognitive function

Disclosed are compositions for promoting general health and well-being, comprising an extract of a botanical raw material, wherein said extract inhibits the carboxyl demethylating activity of a protein phosphatase, and methods of making and using same.

Growing community of inventors

Princeton, NJ, United States of America

Jeffry B Stock